Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash & Equivalents (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Cash & Equivalents for 6 consecutive years, with $20.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 54.75% year-over-year to $20.5 million, compared with a TTM value of $20.5 million through Sep 2025, up 54.75%, and an annual FY2024 reading of $26.3 million, up 8.06% over the prior year.
  • Cash & Equivalents was $20.5 million for Q3 2025 at Ovid Therapeutics, down from $28.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $233.1 million in Q1 2021 and bottomed at $13.2 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $82.0 million, with a median of $57.4 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 752.52% in 2021, then tumbled 77.63% in 2022.
  • Year by year, Cash & Equivalents stood at $187.8 million in 2021, then crashed by 77.63% to $42.0 million in 2022, then plummeted by 42.07% to $24.3 million in 2023, then grew by 8.06% to $26.3 million in 2024, then dropped by 22.12% to $20.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for OVID at $20.5 million in Q3 2025, $28.4 million in Q2 2025, and $18.9 million in Q1 2025.